Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
Mayo Clinic
Mayo Clinic
Columbia University
Washington University School of Medicine
Columbia University
Yale University
National Cancer Institute (NCI)